Cargando…
Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study
PURPOSE: To compare the outcomes of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) with and without microwave ablation (MWA) for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer (ASTRI-NSCLC). MATERIALS AND METHODS: A total of 77 AS...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965054/ https://www.ncbi.nlm.nih.gov/pubmed/35371971 http://dx.doi.org/10.3389/fonc.2022.851830 |
_version_ | 1784678348774965248 |
---|---|
author | Xu, Sheng Bie, Zhi-Xin Li, Yuan-Ming Li, Bin Kong, Fan-Lei Peng, Jin-Zhao Li, Xiao-Guang |
author_facet | Xu, Sheng Bie, Zhi-Xin Li, Yuan-Ming Li, Bin Kong, Fan-Lei Peng, Jin-Zhao Li, Xiao-Guang |
author_sort | Xu, Sheng |
collection | PubMed |
description | PURPOSE: To compare the outcomes of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) with and without microwave ablation (MWA) for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer (ASTRI-NSCLC). MATERIALS AND METHODS: A total of 77 ASTRI-NSCLC patients who received DEB-BACE combined with MWA (group A; n = 28) or DEB-BACE alone (group B; n = 49) were included. Clinical outcomes were compared between groups A and B. Kaplan–Meier methods were used to compare the median progression-free survival (PFS) or overall survival (OS) between the two groups. Univariate and multivariate Cox proportional hazards analyses were used to investigate the predictors of OS for ASTRI-NSCLC treated with DEB-BACE. RESULTS: No severe adverse event was found in both groups. Pneumothorax was the predominant MWA-related complication in group A, with an incidence rate of 32.1% (9/28). Meanwhile, no significant difference was found in DEB-BACE-related complications between groups A and B. The overall disease control rate (DCR) was 61.0% (47/77), with a significantly higher DCR in group A (85.7% vs. 46.9%, P = 0.002). The median PFS in groups A and B was 7.0 and 4.0 months, respectively, with a significant difference (P = 0.037). The median OS in groups A and B was both 8.0 months, with no significant difference (P = 0.318). The 6-month PFS and OS rates in groups A and B were 75.0% and 78.6%, 22.4% and 59.2%, respectively, while the 12-month PFS and OS rates in groups A and B were 17.9% and 28.6%, 14.3% and 22.4%, respectively. Of these, a significantly higher 6-month PFS rate was found in group A (75.0% vs. 22.4%; P < 0.001). The cycles of DEB-BACE/bronchial artery infusion chemotherapy [hazard ratio (HR): 0.363; 95% confidence interval (CI): 0.202–0.655; P = 0.001] and postoperative immunotherapy (HR: 0.219; 95% CI: 0.085–0.561; P = 0.002) were identified as the predictors of OS in ASTRI-NSCLC treated with DEB-BACE. CONCLUSION: MWA sequentially combined with DEB-BACE was superior to DEB-BACE alone in the local control of ASTRI-NSCLC. Although the combination therapy reveals a trend of prolonging the OS, long-term prognosis warrants an investigation with a longer follow-up. |
format | Online Article Text |
id | pubmed-8965054 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89650542022-03-31 Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study Xu, Sheng Bie, Zhi-Xin Li, Yuan-Ming Li, Bin Kong, Fan-Lei Peng, Jin-Zhao Li, Xiao-Guang Front Oncol Oncology PURPOSE: To compare the outcomes of drug-eluting bead bronchial arterial chemoembolization (DEB-BACE) with and without microwave ablation (MWA) for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer (ASTRI-NSCLC). MATERIALS AND METHODS: A total of 77 ASTRI-NSCLC patients who received DEB-BACE combined with MWA (group A; n = 28) or DEB-BACE alone (group B; n = 49) were included. Clinical outcomes were compared between groups A and B. Kaplan–Meier methods were used to compare the median progression-free survival (PFS) or overall survival (OS) between the two groups. Univariate and multivariate Cox proportional hazards analyses were used to investigate the predictors of OS for ASTRI-NSCLC treated with DEB-BACE. RESULTS: No severe adverse event was found in both groups. Pneumothorax was the predominant MWA-related complication in group A, with an incidence rate of 32.1% (9/28). Meanwhile, no significant difference was found in DEB-BACE-related complications between groups A and B. The overall disease control rate (DCR) was 61.0% (47/77), with a significantly higher DCR in group A (85.7% vs. 46.9%, P = 0.002). The median PFS in groups A and B was 7.0 and 4.0 months, respectively, with a significant difference (P = 0.037). The median OS in groups A and B was both 8.0 months, with no significant difference (P = 0.318). The 6-month PFS and OS rates in groups A and B were 75.0% and 78.6%, 22.4% and 59.2%, respectively, while the 12-month PFS and OS rates in groups A and B were 17.9% and 28.6%, 14.3% and 22.4%, respectively. Of these, a significantly higher 6-month PFS rate was found in group A (75.0% vs. 22.4%; P < 0.001). The cycles of DEB-BACE/bronchial artery infusion chemotherapy [hazard ratio (HR): 0.363; 95% confidence interval (CI): 0.202–0.655; P = 0.001] and postoperative immunotherapy (HR: 0.219; 95% CI: 0.085–0.561; P = 0.002) were identified as the predictors of OS in ASTRI-NSCLC treated with DEB-BACE. CONCLUSION: MWA sequentially combined with DEB-BACE was superior to DEB-BACE alone in the local control of ASTRI-NSCLC. Although the combination therapy reveals a trend of prolonging the OS, long-term prognosis warrants an investigation with a longer follow-up. Frontiers Media S.A. 2022-03-15 /pmc/articles/PMC8965054/ /pubmed/35371971 http://dx.doi.org/10.3389/fonc.2022.851830 Text en Copyright © 2022 Xu, Bie, Li, Li, Kong, Peng and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xu, Sheng Bie, Zhi-Xin Li, Yuan-Ming Li, Bin Kong, Fan-Lei Peng, Jin-Zhao Li, Xiao-Guang Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title | Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title_full | Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title_fullStr | Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title_full_unstemmed | Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title_short | Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study |
title_sort | drug-eluting bead bronchial arterial chemoembolization with and without microwave ablation for the treatment of advanced and standard treatment-refractory/ineligible non-small cell lung cancer: a comparative study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8965054/ https://www.ncbi.nlm.nih.gov/pubmed/35371971 http://dx.doi.org/10.3389/fonc.2022.851830 |
work_keys_str_mv | AT xusheng drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT biezhixin drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT liyuanming drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT libin drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT kongfanlei drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT pengjinzhao drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy AT lixiaoguang drugelutingbeadbronchialarterialchemoembolizationwithandwithoutmicrowaveablationforthetreatmentofadvancedandstandardtreatmentrefractoryineligiblenonsmallcelllungcanceracomparativestudy |